Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease

Vance T Lehman, Rickey E. Carter, Daniel O. Claassen, Robert C. Murphy, Val Lowe, Ronald Carl Petersen, Patrick J. Peller

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

INTRODUCTION: We examined the clinical impact of commercially available quantitation software using 3-dimensional stereotactic surface projection (3D-SSP) on the diagnostic accuracy of F fluorodeoxyglucose positron emission tomography (F FDG PET) in mild cognitive impairment (MCI) and Alzheimer disease (AD). METHODS: Enrollees underwent clinical evaluation to determine cognitive status and subsequent F FDG PET neuroimaging. Four blinded readers (2 novices and 2 experts) rated the images for degree of abnormality and interpretive confidence without and with 3D-SSP. Diagnostic accuracy was determined with area under the curve (area under the curve) of a receiver operating characteristic (receiver operating characteristic) curve analysis and change in confidence with model-based means (LSMeans). RESULTS: Twenty-three normal controls and 31 patients with cognitive impairment (18 MCI and 13 AD) were enrolled (28 female and 26 male; mean age 74 years). During follow-up (mean 3.6 years), all normal participants remained normal, 12 of 18 participants with MCI progressed to dementia, and all participants with baseline dementia progressed. The area under the curve with 3D-SSP (0.88; 95% CI: 0.76-0.95) was significantly higher than without it (0.72; 95% CI: 0.55-0.83). The specificity increased from 26% to 63% for novices and from 56% to 87% for experts with addition of 3D-SSP, whereas the sensitivity was essentially unchanged at 86% and 86% for the beginners and 81% and 79% for the experts. The interpretive confidence increased significantly from 3.3 to 4.0 (maximum value = 5, P = 0.048). CONCLUSION: The use of commercially available 3D-SSP quantitation improved diagnostic accuracy for evaluation of MCI and AD with F FDG PET.

Original languageEnglish (US)
Pages (from-to)721-726
Number of pages6
JournalClinical Nuclear Medicine
Volume37
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Positron-Emission Tomography
Alzheimer Disease
Area Under Curve
ROC Curve
Dementia
Neuroimaging
Software
Cognitive Dysfunction

Keywords

  • 3D-SSP
  • Alzheimer disease
  • brain PET
  • mild cognitive impairment
  • PET
  • stereotactic surface display
  • three-dimensional

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{ef724d24d3304a7797af87294cc45f8c,
title = "Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease",
abstract = "INTRODUCTION: We examined the clinical impact of commercially available quantitation software using 3-dimensional stereotactic surface projection (3D-SSP) on the diagnostic accuracy of F fluorodeoxyglucose positron emission tomography (F FDG PET) in mild cognitive impairment (MCI) and Alzheimer disease (AD). METHODS: Enrollees underwent clinical evaluation to determine cognitive status and subsequent F FDG PET neuroimaging. Four blinded readers (2 novices and 2 experts) rated the images for degree of abnormality and interpretive confidence without and with 3D-SSP. Diagnostic accuracy was determined with area under the curve (area under the curve) of a receiver operating characteristic (receiver operating characteristic) curve analysis and change in confidence with model-based means (LSMeans). RESULTS: Twenty-three normal controls and 31 patients with cognitive impairment (18 MCI and 13 AD) were enrolled (28 female and 26 male; mean age 74 years). During follow-up (mean 3.6 years), all normal participants remained normal, 12 of 18 participants with MCI progressed to dementia, and all participants with baseline dementia progressed. The area under the curve with 3D-SSP (0.88; 95{\%} CI: 0.76-0.95) was significantly higher than without it (0.72; 95{\%} CI: 0.55-0.83). The specificity increased from 26{\%} to 63{\%} for novices and from 56{\%} to 87{\%} for experts with addition of 3D-SSP, whereas the sensitivity was essentially unchanged at 86{\%} and 86{\%} for the beginners and 81{\%} and 79{\%} for the experts. The interpretive confidence increased significantly from 3.3 to 4.0 (maximum value = 5, P = 0.048). CONCLUSION: The use of commercially available 3D-SSP quantitation improved diagnostic accuracy for evaluation of MCI and AD with F FDG PET.",
keywords = "3D-SSP, Alzheimer disease, brain PET, mild cognitive impairment, PET, stereotactic surface display, three-dimensional",
author = "Lehman, {Vance T} and Carter, {Rickey E.} and Claassen, {Daniel O.} and Murphy, {Robert C.} and Val Lowe and Petersen, {Ronald Carl} and Peller, {Patrick J.}",
year = "2012",
month = "8",
doi = "10.1097/RLU.0b013e3182478d89",
language = "English (US)",
volume = "37",
pages = "721--726",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease

AU - Lehman, Vance T

AU - Carter, Rickey E.

AU - Claassen, Daniel O.

AU - Murphy, Robert C.

AU - Lowe, Val

AU - Petersen, Ronald Carl

AU - Peller, Patrick J.

PY - 2012/8

Y1 - 2012/8

N2 - INTRODUCTION: We examined the clinical impact of commercially available quantitation software using 3-dimensional stereotactic surface projection (3D-SSP) on the diagnostic accuracy of F fluorodeoxyglucose positron emission tomography (F FDG PET) in mild cognitive impairment (MCI) and Alzheimer disease (AD). METHODS: Enrollees underwent clinical evaluation to determine cognitive status and subsequent F FDG PET neuroimaging. Four blinded readers (2 novices and 2 experts) rated the images for degree of abnormality and interpretive confidence without and with 3D-SSP. Diagnostic accuracy was determined with area under the curve (area under the curve) of a receiver operating characteristic (receiver operating characteristic) curve analysis and change in confidence with model-based means (LSMeans). RESULTS: Twenty-three normal controls and 31 patients with cognitive impairment (18 MCI and 13 AD) were enrolled (28 female and 26 male; mean age 74 years). During follow-up (mean 3.6 years), all normal participants remained normal, 12 of 18 participants with MCI progressed to dementia, and all participants with baseline dementia progressed. The area under the curve with 3D-SSP (0.88; 95% CI: 0.76-0.95) was significantly higher than without it (0.72; 95% CI: 0.55-0.83). The specificity increased from 26% to 63% for novices and from 56% to 87% for experts with addition of 3D-SSP, whereas the sensitivity was essentially unchanged at 86% and 86% for the beginners and 81% and 79% for the experts. The interpretive confidence increased significantly from 3.3 to 4.0 (maximum value = 5, P = 0.048). CONCLUSION: The use of commercially available 3D-SSP quantitation improved diagnostic accuracy for evaluation of MCI and AD with F FDG PET.

AB - INTRODUCTION: We examined the clinical impact of commercially available quantitation software using 3-dimensional stereotactic surface projection (3D-SSP) on the diagnostic accuracy of F fluorodeoxyglucose positron emission tomography (F FDG PET) in mild cognitive impairment (MCI) and Alzheimer disease (AD). METHODS: Enrollees underwent clinical evaluation to determine cognitive status and subsequent F FDG PET neuroimaging. Four blinded readers (2 novices and 2 experts) rated the images for degree of abnormality and interpretive confidence without and with 3D-SSP. Diagnostic accuracy was determined with area under the curve (area under the curve) of a receiver operating characteristic (receiver operating characteristic) curve analysis and change in confidence with model-based means (LSMeans). RESULTS: Twenty-three normal controls and 31 patients with cognitive impairment (18 MCI and 13 AD) were enrolled (28 female and 26 male; mean age 74 years). During follow-up (mean 3.6 years), all normal participants remained normal, 12 of 18 participants with MCI progressed to dementia, and all participants with baseline dementia progressed. The area under the curve with 3D-SSP (0.88; 95% CI: 0.76-0.95) was significantly higher than without it (0.72; 95% CI: 0.55-0.83). The specificity increased from 26% to 63% for novices and from 56% to 87% for experts with addition of 3D-SSP, whereas the sensitivity was essentially unchanged at 86% and 86% for the beginners and 81% and 79% for the experts. The interpretive confidence increased significantly from 3.3 to 4.0 (maximum value = 5, P = 0.048). CONCLUSION: The use of commercially available 3D-SSP quantitation improved diagnostic accuracy for evaluation of MCI and AD with F FDG PET.

KW - 3D-SSP

KW - Alzheimer disease

KW - brain PET

KW - mild cognitive impairment

KW - PET

KW - stereotactic surface display

KW - three-dimensional

UR - http://www.scopus.com/inward/record.url?scp=84863864346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863864346&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e3182478d89

DO - 10.1097/RLU.0b013e3182478d89

M3 - Article

C2 - 22785496

AN - SCOPUS:84863864346

VL - 37

SP - 721

EP - 726

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 8

ER -